ReShape Lifesciences (RSLS) Competitors $3.16 -0.05 (-1.41%) Closing price 08/14/2025Extended Trading$3.16 0.00 (0.00%) As of 08/14/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock RSLS vs. BIAF, ABT, ISRG, BSX, SYK, MDT, BDX, IDXX, EW, and RMDShould you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include bioAffinity Technologies (BIAF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), and ResMed (RMD). These companies are all part of the "medical" sector. ReShape Lifesciences vs. Its Competitors bioAffinity Technologies Abbott Laboratories Intuitive Surgical Boston Scientific Stryker Medtronic Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences ResMed ReShape Lifesciences (NASDAQ:RSLS) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals and insiders hold more shares of RSLS or BIAF? 22.1% of ReShape Lifesciences shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 0.0% of ReShape Lifesciences shares are held by insiders. Comparatively, 16.9% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor RSLS or BIAF? In the previous week, bioAffinity Technologies had 2 more articles in the media than ReShape Lifesciences. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for ReShape Lifesciences. bioAffinity Technologies' average media sentiment score of 0.16 beat ReShape Lifesciences' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media. Company Overall Sentiment ReShape Lifesciences Neutral bioAffinity Technologies Neutral Do analysts prefer RSLS or BIAF? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ReShape Lifesciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00bioAffinity Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, RSLS or BIAF? ReShape Lifesciences has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReShape Lifesciences$8.01M1.06-$7.13M-$108.27-0.03bioAffinity Technologies$9.36M0.77-$9.04M-$0.70-0.36 Is RSLS or BIAF more profitable? ReShape Lifesciences has a net margin of -69.71% compared to bioAffinity Technologies' net margin of -152.16%. ReShape Lifesciences' return on equity of -547.65% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets ReShape Lifesciences-69.71% -547.65% -79.89% bioAffinity Technologies -152.16%-845.68%-181.92% Which has more risk & volatility, RSLS or BIAF? ReShape Lifesciences has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500. SummaryReShape Lifesciences and bioAffinity Technologies tied by winning 7 of the 14 factors compared between the two stocks. Get ReShape Lifesciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RSLS vs. The Competition Export to ExcelMetricReShape LifesciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.49M$7.05B$5.82B$9.74BDividend YieldN/A1.30%3.84%4.09%P/E Ratio-0.0327.1631.1525.97Price / Sales1.06145.24475.57123.18Price / CashN/A21.6837.1558.38Price / Book-0.366.869.116.39Net Income-$7.13M$176.42M$3.26B$265.66M7 Day Performance-75.00%0.58%2.11%1.98%1 Month Performance-73.88%-0.45%5.12%1.33%1 Year Performance-99.68%13.07%31.25%21.15% ReShape Lifesciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RSLSReShape Lifesciences0.0637 of 5 stars$3.16-1.4%N/A-99.7%$8.49M$8.01M-0.0350Stock SplitGap DownHigh Trading VolumeBIAFbioAffinity Technologies0.3606 of 5 stars$0.25+5.1%N/A-85.7%$6.63M$9.36M-0.3510Gap UpABTAbbott Laboratories4.907 of 5 stars$130.32-1.1%$144.47+10.9%+18.5%$229.31B$41.95B16.33114,000Positive NewsISRGIntuitive Surgical4.8892 of 5 stars$481.28+0.2%$595.95+23.8%-3.6%$172.16B$8.35B67.1215,638Trending NewsAnalyst ForecastBSXBoston Scientific4.724 of 5 stars$103.06-0.1%$117.50+14.0%+33.5%$152.87B$18.49B61.3553,000Positive NewsSYKStryker4.4849 of 5 stars$381.91flat$430.10+12.6%+11.4%$146.01B$23.82B50.5853,000Positive NewsMDTMedtronic4.8084 of 5 stars$92.74-0.3%$98.19+5.9%+4.1%$119.23B$33.54B25.6295,000Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionBDXBecton, Dickinson and Company4.3771 of 5 stars$195.22-0.4%$211.44+8.3%-16.3%$56.16B$20.18B35.1174,000Positive NewsIDXXIDEXX Laboratories4.3935 of 5 stars$637.86-2.0%$649.44+1.8%+27.9%$52.07B$3.90B53.1111,000Positive NewsEWEdwards Lifesciences4.5079 of 5 stars$78.30+0.0%$85.90+9.7%+15.8%$45.95B$5.69B11.2715,800Positive NewsAnalyst RevisionRMDResMed4.6996 of 5 stars$286.17+0.4%$274.83-4.0%+28.5%$41.71B$5.15B30.0910,600News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies BIAF Alternatives ABT Alternatives ISRG Alternatives BSX Alternatives SYK Alternatives MDT Alternatives BDX Alternatives IDXX Alternatives EW Alternatives RMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RSLS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access